Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A systematic review of historical and contemporary evidence of trachoma endemicity in the Pacific Islands

  • Becca L. Handley ,

    Roles Conceptualization, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing

    Rebecca.handley1@lshtm.ac.uk

    Affiliation Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

  • Chrissy h. Roberts,

    Roles Conceptualization, Methodology, Resources, Supervision, Visualization, Writing – review & editing

    Affiliation Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

  • Robert Butcher

    Roles Conceptualization, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing

    Affiliation Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

A systematic review of historical and contemporary evidence of trachoma endemicity in the Pacific Islands

  • Becca L. Handley, 
  • Chrissy h. Roberts, 
  • Robert Butcher
PLOS
x

Abstract

Introduction

Trachoma is endemic in several Pacific Island countries. The aims of this study were to (a) identify future trachoma mapping needs in the Pacific and (b) to examine whether any temporal trends in trachoma prevalence could be ascertained from the historical literature on trachoma in the Pacific Islands.

Methods

Human studies of trachoma and eye care in the Pacific Islands were identified from a systematic search of PubMed, EMbase, Scopus and Web of Science databases. A published quality assessment system for disease prevalence studies was modified to assess studies for quality and transparency.

Results

Few general ophthalmic studies in the Pacific mention trachoma. In targeted studies of trachoma, cases have consistently been identified throughout the Pacific since the early twentieth century. The largest number of studies come from Papua New Guinea and Fiji, whereas some countries have no published data on trachoma. The majority of studies identified were published before the Alliance for the Global Elimination of Trachoma 2020 was convened, so lack the standardisation of population-based mapping which has been implemented in the past decade.

Conclusions

Population-based trachoma prevalence estimates have been recently generated in Papua New Guinea, Solomon Islands, Vanuatu, Kiribati and Fiji. There is insufficient evidence to assess whether there has been temporal change in trachoma prevalence in these countries over the past century. Cases of trachoma have been identified in some countries (for example, Nauru and Samoa) which have no recent population-based mapping data, but may be at risk of trachoma endemcitiy. Deployment of appropriate mapping strategies is warranted to identify whether interventions are required.

Introduction

Trachoma is a chronic keratoconjunctivitis caused by ocular serovars (A-C) of Chlamydia trachomatis (Ct). Infection with Ct is most common in young children and results in follicular and papillary inflammation. Repeated rounds of infection, inflammation and resolution can lead to conjunctival scarring and may eventually cause eyelashes to turn inward and abrade the globe of the eye. Abrasion from eyelashes can cause opacification of the cornea, the sight-threatening stage of trachoma [1]. Over the past two decades, there has been a concerted global effort to eliminate blinding trachoma as a public health problem by 2020. This is supported by the WHO-led Global Elimination of Trachoma by 2020 (GET2020) Alliance, convened in 1996 [2], and by World Health Assembly resolution 51.11 which was passed in 1998 [3]. An effective package of community-wide control interventions has also been developed and this is known as the ‘SAFE’ strategy. SAFE denotes: Surgery to treat those suffering with trachomatous trichiasis (TT), mass drug administration (MDA) with Antibiotics, promotion of Facial cleanliness and Environmental improvement to reduce prevalence and transmission of the causative agent [4]. The WHO Simplified Grading Scheme [5], a standardisable, scalable diagnostic system, has been used in the generation of high-quality, district-level maps of trachoma prevalence. Current recommendations suggest implementation of the SAFE strategy to reduce the population prevalence of TT to <0.1% and the prevalence of trachomatous inflammation–follicular (TF) in 1–9 year olds to <5% [6]. Although perhaps not on course for global elimination by 2020, overall progress towards the goal is good. Much of the research and focus of trachoma control efforts takes place in Africa, where the majority of the global burden of disease persists [7]; however, trachoma studies are lacking in several other regions.

The Pacific region consists of thousands of volcanic islands and coral atolls dispersed over vast seas. Demographically, these islands are mainly populated by individuals descended from one of three genetically distinct indigenous ethnicities: Melanesian, Polynesian and Micronesian [8]. The region faces unique challenges in the provision of eyecare services due to its geography. A 2014 review of visual impairment in the Pacific suggested that 0.5–1.2% of the Pacific Island population were blind [9]. In that study, the leading causes of blindness were listed as cataracts (responsible for 40.6% of blindess), uncorrected refractive error (13.6%), macular degeneration (4.6%), glaucoma (4.2%) and diabetic retinopathy (1.2%). Recent Global Trachoma Mapping Project (GTMP) and International Agency for the Prevention of Blindness (IAPB) surveys have indicated that TF remains widespread throughout the region, but these surveys also suggested that the prevalence of TT and ocular Ct infection were low given the corresponding TF prevalences [1016]. This discrepant clinical presentation presents a problem for policymakers, as they must decide whether to implement costly community-wide treatment strategies in a region where the correlation between clinical signs and risk of sight-threatening disease is unclear. For these reasons, during a 2018 meeting convened by the WHO, local stakeholders endorsed the inclusion of infection testing and more detailed investigation into the presentation of trachoma to determine whether implementation of the SAFE strategy is appropriate [17]. Recent surveys in the Pacific have also highlighted how trachoma prevalence could be unevenly distributed between neighbouring islands or regions of the same nation [10,16]. This is perhaps unsurprising given the geographical isolation of many of the islands, but raises questions regarding whether data from population-based surveys of island chains can be legitimately extrapolated to wider regions or nationally.

This study has systematically reviewed historical and contemporary literature on trachoma in the Western Pacific. Our aim was to provide an overview of the current epidemiological picture with a historical context that may help with the interpretation of the unusual clinical data observed in some surveys. By amalgamating trachoma data collected over the past century, we attempted to investigate temporal trends. Further, by identifying a number of populations for which very little or no data exists, we hoped to highlight underserved regions and nations which may need mapping. To better understand the relative contribution of trachoma to overall blindness rates in the Pacific, we chose to include in our review all studies of visual impairment and blindness that focus on this region.

Methods

Scope of the review

The review focuses on states in the Pacific. For the purposes of this review, we focussed on members of the Secretariat of the Pacific Community (SPC) [18]. The current population, political status [19]and trachoma-endemicity status (according to the Global Health Observatory [20]) of each state included in this review are displayed in Table 1. The USA (except Hawaii, due to its large Polynesian population), France, New Zealand and Australia are members of the SPC but were excluded as they do not share sociodemographic, economic and/or geographic characteristics with the target states. Both those classified as endemic and non-endemic for trachoma were included in the search terms to improve our understanding of the spatial and temporal distribution of trachoma throughout the region.

Search strategy

The PRISMA guidelines were used to develop a search strategy for this review (S1 Table) [21]. Literature searches were conducted in parallel by two independent investigators. Final decisions on article inclusion were made following discussion between the two investigators. Searches of publicly-available information were conducted using PubMed, EMbase, Scopus and Web of Science. The following search terms were used:

  • Trachoma OR (ocular AND trachomatis) OR Blindness OR conjunctivitis OR “eye disease” OR “visual impairment” OR “neglected tropical disease”
  • AND Pacific OR Polynesia OR Micronesia OR Melanesia OR “American Samoa” OR “Cook Islands” OR “Federated States of Micronesia” OR Fiji OR “French Polynesia” OR Guam OR Kiribati OR “Marshall Islands” OR Nauru OR “New Caledonia” OR Niue OR “Northern Mariana Islands” OR Palau OR “Papua New Guinea” OR “Pitcairn Islands” OR Samoa OR “Solomon Islands” OR Tokelau OR Tonga OR Tuvalu OR Vanuatu OR “Wallis and Futuna”

Only human studies were included in this review. All studies published before 1st July 2018 were eligible for inclusion. Studies published prior to 1996 (when the WHO convened the alliance for the GET2020 campaign) will be referred to as ‘historical’ studies; those published after will be referred to as ‘contemporary’ studies. The study includes articles not written in English. Reference lists of identified articles were screened for further publications of interest. Manual searches to identify any other relevant material for inclusion were conducted.

Data extraction and quality assessment

Criteria for assessing the quality of shortlisted studies which describe trachoma prevalence were set out prior to data extraction. These criteria, described in S2 Table, were based on published objective criteria for assessing population prevalence studies for systematic reviews [22]. Relevant information on clinical epidemiology of trachoma was extracted from shortlisted articles. The synthesis of data was primarily descriptive; meta-analysis of risk factors was beyond the scope of this review.

Results

The number of articles included in each stage of the systematic review process is described in Fig 1. From 1383 records identified with the initial search terms, 66 articles were eventually included in this review. Included articles were published between 1914 and 2018, with the period 2008–2018 having the highest frequency of included publications. An additional three papers, two doctoral theses, one report and one book section were found within the reference lists of the chosen full texts and were also included. The included articles are summarised in S3 Table. National-level outcomes are summarised in Fig 2.

thumbnail
Fig 1. Flowchart of articles included in this systematic review and key reasons for exclusion at each stage.

https://doi.org/10.1371/journal.pone.0207393.g001

thumbnail
Fig 2. National-level summary of trachoma status following data extraction.

Red: contemporary evidence of trachoma, current status unclear; yellow: some endemic districts, further mapping required, interventions not yet started; green: mapping complete, interventions implemented; blue: historic evidence of trachoma cases, no published contemporary data, current classification non-endemic; grey: no data or no reference to trachoma in available data or current classification non-endemic. Shapefiles downloaded from gadm.org and reproduced under a CC BY 4.0 license with permission from Dr Robert Hijmans. Map prepared in Miller projection using QGIS 2.16 [23].

https://doi.org/10.1371/journal.pone.0207393.g002

Quality assessment

The papers identified were a collection of laboratory studies, prevalence surveys, observational studies, conference abstracts and reviews. Of five reviews identified, three were specific to the Pacific [9,24,25] and two were reviews on trachoma or causes of visual impairment worldwide [26,27]. The primary publications relevant to the Pacific reviewed in these five articles were identified separately in this literature search. 35 articles specifically investigated trachoma. Prevalence estimates comparable to current mapping standards could only be derived from 8/66 studies (12.1%). Seven trachoma-specific population based prevalence surveys (PBSPs) were identified, five of which provided data from surveys related to the GTMP. A number of common issues precluded a number of studies generating prevalence estimates comparable to contemporary mapping standards. Five studies aimed to determine trachoma prevalence but only examined school attendance, thereby potentially missing trachoma cases where school attendance is low. Several papers either did not quantify the number of cases of trachoma, did not describe the specific clinical signs that were assessed, or did not provide sufficient description of methodology to indicate that trachoma was systematically assessed. Where trachoma data were presented as part of wider surveys surrounding visual impairment, the method of sample selection or data presentation were frequently inadequate to estimate prevalence. Many of the historical papers which specifically investigated trachoma failed to provide adequate detail on survey design, populations assessed and standardisation of grading, therefore, could not provide prevalence estimates comparable to recent mapping. Some historical studies did provide crude proportions, but did not use appropriate sampling methodology to extrapolate to district-wide prevalence with confidence.

Melanesia

The majority of historical studies in this review focus on Papua New Guinea (PNG) and Fiji. One study from New Caledonia described cases of conjunctivitis from Ct, but did so in the context of urogenital strains infecting the eyes of neonates after birth [28]. Another extensive series of studies described the distribution of trachoma throughout Western New Guinea in 1964. This study revealed several areas where a high proportion of people had either clinical signs of trachoma, inclusion bodies, or both [29]. Western New Guinea is predominantly inhabited by people of Melanesian ethnicity, but is not within the scope of this review as it is part of Indonesia.

Papua New Guinea.

Consecutive analyses of ophthalmic patient records (covering several regions between 1975 and 1991) consistently reported that trachoma was a minor contributor to visual impairment throughout PNG [3032]. Exceptional areas where cases of entropion were found (for example, West Sepik and New Britain) were highlighted by the authors of these studies [32]. In their 1980s review of ophthalmic records in PNG, Parsons said “Trachoma is mentioned only to emphasise its relative unimportance in [PNG]” [32]. In outreach clinics which operated between 2011 and 2013, 35 cases of trachoma (clinical grade not specified) were identified from a single clinic. Despite identifying cases, no TT corrective surgeries were performed [33]. Surveys of visual impairment have also taken place in PNG, including a survey of over 3000 adults in Hanubada, Rigo, Rabaul and Teleformin regions (1979–1980). Participants were systematically and specifically examined for trachoma and other ocular morbidities. From that survey, Dethlefs asserted trachoma was found to be endemic in all areas studied, but was of “mild intensity and rarely caused visual deficit” [34]. More recently, a survey determining the causes of vision loss in older people living in the Port Moresby and Rigo coastal districts of PNG found cataracts and uncorrected refractive errors were the leading causes of visual impairment. Trachoma was not mentioned in this study [35]. During a Rapid Assessment of Avoidable Blindness in PNG, one case of trachomatous corneal opacity was found among 4818 survey participants aged ≥50 years from across the country, accounting for 0.8% of cases of blindness [36].

A number of surveys specifically focussed on trachoma have been conducted in PNG. Mann undertook extensive trachoma surveys throughout the country in the 1950s [3740]. The surveys took place in the Marshall Bennett Islands, Trobriand Islands (Kitava and Woodlark), Samarai Island, Admirality Islands, Duke of York Islands, New Britain, New Ireland and Mainland PNG (The Highlands, Port Moresby, Sepik, Telefomin and Baiyer River). In total, over the 14 areas surveyed, 13,268 people were examined for clinical signs of trachoma using Mann’s own grading system [37] which was modified from MacCallan’s scheme [41]. The prevalence of trachoma (clinical grade not specified) ranged from 8.5% in the Marshall Bennett Islands to 85.8% in Teleformin. Although some of these estimates were extremely high, only 15 individuals suffered with bilateral blindness from trachoma. Mann stated that, in general, trachoma in PNG was “mild and self-healing”, with the exception of New Britain, where the blinding sequelae were common. Mann speculated that the geographic heterogeneity in prevalence was due to time since introduction of the disease to the different areas [40]. A survey in 30 accessible schools in Madang Province estimated 9.6% of 6153 surveyed children (mean age 10 years) to have moderate to severe trachoma (F3/F4 [F4 defined in this study as the total confluence of follicles on the tarsus] or P3) [42]. In 1971, a trachoma survey was conducted in a single village on one of the Admiralty Islands, all grades of trachoma according to the MacCallan grading scheme were rare [43]. This was in contrast to Mann’s survey data which found 64% of the 801 people examined on the Admirality Islands had trachoma (clinical signs not specified) [37].

A 2015 PBPS took place in six evaluation units (EUs) of PNG under the GTMP [16]. Overall 6555 children aged 1–9 years were examined alongside 8059 adults. Four of the EUs surveyed had TF prevalences of over 10%, these were Western Province, Southern Highlands (East), Southern Highlands (West) and West New Britain. Only Madang and National Capital districts had a prevalence of less than 10%. Across the entire survey, only four cases of TT were seen and these were all found in West New Britain, part of the only region where Mann found severe blinding trachoma [37]. The GTMP study also showed a strong association between unimproved sanitation and an increased risk of TF in children aged 1–9 years [16].

Fiji.

A 1986 hospital-based study [44], found trachoma in 0.34% of the 800 patients (of all ages) surveyed. Surveys of blindness (outpatient questionnaires and hospital record screening) in Fiji rarely mention trachoma, with cataracts and refractive errors responsible for the majority of causes of visual impairment in both adults [45,46] and children [47]. Only two cases of trachoma (clinical grade not specified) were seen at outreach clinics 2011 and 2013, and neither underwent tarsal rotation surgery [33].

The earliest studies focussing specifically on trachoma were published in the 1930s [48,49]. These are both descriptive reports incorporating the authors’ clinical experiences with reports from medical colleagues working in-country. Neither presented any primary epidemiological data, although Stuppel published photographs of individuals with eye disease, at least one of which appeared to be a clear example of TT. Both studies concluded that trachoma was prevalent in Fiji [48,49]. Two studies which took place shortly after World War II examined trachoma in small groups of indigenous Fijians and also in expatriate American and New Zealand servicemen living in military facilities on Viti Levu. Transmission to visiting servicemen appeared, to these authors, to be nearly absent but clinical signs were seen in a high proportion of the Fijian study participants [50,51]. Prowasek-Halberstader inclusions were found in some cases with and without trachoma, and were associated with having trachoma [50].

The first estimates of trachoma prevalence in what might now be classed as a district- or sub-district-level population came from surveys in Viti Levu. These surveys used systematic grading systems or variations thereof such as Mann [37] Ching [52] to characterise trachoma. Swanston found 39% of almost 1400 people of all ages had clinical signs of trachoma including healed (scarred) trachoma [37,53]. Ward estimated a similar prevalence of trachoma at 35% in those under the age of 20 (although the author does not specify which grades), and almost 90% of those over the age of 60 (again the author does not specify the grade) [37,54]. Ward suggests in his report that the relatively high prevalence of trachoma in adults compared with the lower prevalences of active disease in children may indicate an improvement in living conditions in recent years resulting in a reduced incidence of active disease. Neither of these two studies demonstrate sufficiently random participant recruitment nor adjustment for age or gender to compare to modern prevalence estimates.

A trachoma rapid assessment (TRA) in 2007 demonstrated that active trachoma was present in the Western Division of Fiji [55]. No cases of trichiasis were found in 319 adults examined, although analysis of medical records demonstrated that surgical management of some TT cases had occurred in the three years preceding the survey [55]. Following this, a nation-wide survey was conducted in 2012 [10,15] and this reported estimates of TF prevalences exceeding 10% among 1 to 9 year-olds in all four Divisions of the country (mean: 15.4%, range: 10.4 [Suva]– 20.9% [Northern Division]). The survey also reported that in some regions active trachoma was more prevalent among people of the iTaukei ethnic group than among Indian Fijians but this was not a consistent across the Fijian divisions. Common household-level risk factors for trachoma, such as lack of availability of clean water or lack of facilites for disposal of human waste, were not found to be common in Fiji [10,15].

The Western and Northern Divisions of Fiji were shown to have very high TT prevalence (8.7% and 6.2%, respectively). However the authors treated this estimate with caution due to poor correlation with the relatively low TF estimates [15]. It was subsequently shown that a common sociocultural practice of eyelash epilation was prevalent in the Western Division of Fiji. A 2017 study [56] demonstrated that many Fijians who epilated (and who would have been classified as TT cases) in fact had no signs of scarring or entropion and were unlikely to be self-treating for the condition.

The Western Division was re-surveyed by PBPS in 2013 and conjunctival swabs were collected to assess the prevalence of ocular Ct infection with nucleic acid amplification tests (NAATs) [13]. This survey found ocular Ct to be rare (adjusted prevalence 2.3%), but, interestingly, also found TF and TT were much lower than the previous national survey had found (TF was only 2.9% in 1–9-year-olds compared with 19.6% seen in Western Province during the previous PBPS [10,15]). Serological data suggested that approximately 15% of 1-year-olds had been exposed to Ct at some point and that transmission of Ct between the ages of 1–15 years was likely to be very low [57]. The discrepancy between the two most recent population surveys of clinical trachoma is surprising and it is hard to understand how such a large difference could be explained by simple experimental variation, such as selection of clusters with differing TF prevalence by random chance. One key difference between the two studies was that the later survey utilised a standardised training scheme to ensure TF grading was as consistent as possible with surveys going on elsewhere in the world (i.e., GTMP compliance).

Solomon Islands.

Subsequent to the initial report that suggested trachoma may be present in the Solomon Islands [49], Verlee and colleagues [58] examined trachoma in 600 people from inland villages in Bougainville (geographically part of the Solomon Island archipelago) and Malatia. Although the authors subsequently noted that trachoma was prevalent in other villages nearer the coast in those areas [59], they found no cases of trachoma in their initial survey. Serum samples and conjunctival scrapes taken from participants in the Solomon Islands, Indonesia, Australia and Tunisia were all used to test new culture methods for the isolation of Ct in the 1970s. Ct was isolated from a small number of Solomon Islander specimens collected from individuals with moderately severe active trachoma [60].

More recently, surgical outreach teams operating in the Solomon Islands carried out bilamellar tarsal rotation surgery on nine adults presenting for surgery with trachomabetween 2011 and 2013 [33]. Trachoma was confirmed as endemic when, in 2007, a TRA was conducted in nine of the 10 provinces of the Solomon Islands [55,61]. The published data from Malaita, Guadalcanal and Western provinces indicated that scarring was highly prevalent in adults living in the selected study villages, but did not identify a significant burden of TT, either during the survey, or in the prior analysis of hospital records. The scarcity of TT was such that the doctoral candidate who conducted the survey recommended infection testing in their thesis conclusion [62], and this was the subsequent topic of another doctoral thesis completed in 2017 [63]. In 2013, triggered by the TRA findings, PBPS took place in all provinces of the Solomon Islands. All provinces except Choiseul were found to have TF prevalence above 10% in the 1–9-year-old age group [10,12]. During the IAPB surveys in Malaita, Guadalcanal, Central Islands, Makira, Honiara City and Isabel provinces, data were collected on potential household risk factors for trachoma but association between these and TF were not formally evaluated. In Western, Choiseul, Temotu and Rennell and Bellona, household-level water, sanitation and hygiene data were also collected, but none of the variables measured were associated with increased risk of TF in the household. The TT prevalence in those aged >15 years in all EUs (Western, Choiseul, Temotu and Rennell and Bellona, Guadalcanal and Makira) was below 0.2% [10,12]. In Isabel province, the unadjusted TT prevalence was 0.3% [10].

The paucity of TT, despite the significant burden of TF, provided the impetus for a programme of research which questioned the aetiology of TF. This programme aimed to re-assess the burden of TF and test association with ocular infections, including direct quantitative NAATs for Ct infection. The prevalence of ocular Ct infection in children under 10 years-old in Temotu, Rennell and Bellona was 1.3%, and infection was significantly associated with TF. The authors considered this to be much lower than may have been expected in an area where TF was common [14]. A recent study found no association between severe scarring, classed using the FPC grading system [64,65], and age [66]. Seroepidemiological analyses also provided little evidence of ongoing intense transmission of infection [66,67]. Other pathogens (Adenoviridae, coagulase-negative Staphylococcus, Haemophilus influenza, Moraxella catarrhalis, Staphylococcus pneumonia and Staphylococcus aureus) were sought in these samples using PCR, but none appeared to have significant association with TF. There was also scant evidence for conjunctival dysbiosis, a characteristic disease-associated disturbance of the microbiological community [67]. A recent analysis of gene expression in the conjunctival epithelium of Solomon Islander Ct-negative TF cases provided no evidence of an allergic aetiology [68]. Whilst the causative factor of TF in these regions of the Solomon Islands remains unknown, it seems unlikely that the majority of clinical signs can be attributed to Ct, any other bacterial pathogen, or allergies; further work may be required to determine the aetiology of the disease.

Vanuatu.

In 1989 a survey was carried out to determine the leading causes of blindness in the country. Cataracts was found to be responsible for 85% of binocular blindness and 67% of monocular blindness. Trachoma caused no binocular blindness but was found to be responsible for 5 cases (9%) of monocular blindness [69]. An evaluation of the first five years of a national eye care programme implemented in Vanuatu [70] also highlighted cataracts as the leading diagnosis from outpatient consultations, responsible for 25% of blindness. This study, however, found no cases of trachoma from the 29,109 records analysed. An outreach clinic survey showed that between 2011–2013, four cases of TT were seen, three of which underwent surgical treatment to correct the trichiasis [33].

In 2007 trachoma was studied in isolation during a TRA in Shefa and Tafea provinces [55]. Cases of TF, TI, TS and TT confirmed trachoma to be endemic, leading the Ministry of Health to utilise the GTMP platform to survey the entire country (excluding Luganville, Port Vila and Tafea province) in 2014. The adjusted prevalence of TF was 12%, and only two cases of TT were found in the ≥15-year-olds, an adjusted prevalence of 0.04%. TF was associated with living in a household with an unimproved latrine and larger family size. Older children in the 1–9 age group were also more likely to have TF than younger children in that age group [11].

Micronesia

There are few studies on eye health in Micronesia. The US territories of Guam and the Northern Mariana Islands were not the subject of any of the articles included in this review.

Federated states of micronesia, palau and the marshall Islands.

These countries are listed as non-endemic in the Global Health Observatory [20]. No publications that directly surveyed trachoma were found during this review. However, two general eye health surveys were identified. In 1987, a survey took place in Wotje Atoll of the Marshall Islands group. The project surveyed 400 indigenous adults and found the main causes of visual impairment to be uncorrected refractive error and cataracts. Cases of corneal opacity were reported in 24 people, many of which were bilateral. None of these cases were described as having the characteristic scarring patterns that are typical of trachoma [71]. Another study summarised data from 18 successive rounds of annual outreach clinics in the Federated States of Micronesia, Palau and Marshall Islands. Around 14,000 patients presented for assessment, from whom 2457 blind or visually impaired eyes were identified. Over half of these were due to cataracts, and the second most common cause (14% of eyes with low vision, 11% of blind eyes) was corneal opacity. The authors do not identify the aetiology of corneal opacity, but suggest that trachoma could be one of a number of key causes [72].

Kiribati.

The first report of trachoma in Kiribati was from a field visit by Thylefors in 1989, who noted that 42% of an unspecified number of school children had evidence of TF and 4% had TI [73]. More recent data from a limited number of charitable outreach clinics in Kiribati indicated that there were no cases of trichiasis requiring surgery during 2013 [33]. An abstract presented at the 2014 Annual Congress of the Royal Australian and New Zealand College of Ophthalmologists did not mention trachoma as a cause of blindness in a random sample of 800 adults living in South Tarawa [74].

In 2007, a TRA was conducted in two districts of South Tarawa; cases of TF and TT were found [55]. A more detailed PBPS of South Tarawa and Betio [10] suggested that 22% of children aged 1–9 had TF and that of 959 people aged >15, around 1.5% had TT. Given the association between female gender and TT [75], this may be a slight overestimate as 94.4% of adult participants were female. Several environmental risk factors were observed as being prevalent among households that were surveyed in this study [10]. A second survey [76] was conducted in the major population hub of the Line Island group, Kiritimati Island. The age-adjusted prevalence of TF and TT was 29% and 0.2%.respectively. In those with TF, almost 50% had current ocular Ct infection. The prevalence of Ct infection throughout the surveyed child population was 27%. Seroreactivity to chlamydial antigen Pgp3 increased sharply between the ages of 1 and 6, and the majority of children were exposed by the age of 9, suggesting intense transmission of Ct among children in these communities.

Nauru.

Nauru was included in the 2007 Pacific-wide TRA. Cases of TF were found in communities in four districts. However, very few cases of scarring and no cases of TT were found during the survey. Additionally, no cases of TT surgery were recorded at the Nauru Hospital over the four years preceding the survey [55].

Polynesia

No published data were found on eyecare or trachoma in Tuvalu, French Polynesia, Wallis and Futuna or the Pitcairn Islands.

American Samoa.

One early trachoma survey in American Samoa identified numerous cases of papillary trachomatous inflammation (MacCallan grade IIb). Harbert also indicated that the Department of Health in American Samoa had been investigating trachoma prior to that study [77]. In 1945, 422 inhabitants of American Samoa were surveyed to estimate trachoma prevalence. 217 participants showed signs of trachoma but neither the age or gender of the participants, nor the grading system that was used, were clear. Mann estimated 5% of blindness cases to be caused by trachoma, but it was subsequently suggested that this might be related to a social practice in which wooden picks are inserted beneath the eyelid to ‘alleviate irritation’. [37]. In 1975 a survey was designed to estimate trachoma prevalence in school-aged children from two islands (Tutuila and Ta’u) [78]. This involved examining 1030 school children (aged 3–19) from eight schools. The prevalence of active trachoma ranged from 9–42% and conjunctival scarring was seen in a number of children, however no trichiasis was seen. 154 adults were recruited from a local hospital, 12 of these with specific eye diseases and the remainder randomly selected in- or out-patients seen during the survey duration. Of these, 45 had evidence of past trachoma (e.g. pannus, conjunctival scarring or trichiasis) and four of these were blind as a result severe TT. Two of these individuals were seeking treatment at the time.

Cook Islands.

A 1951 general survey of infectious diseases included conjunctivitis in the list of conditions that were studied. This survey was carried out in a single village on Rarotonga, the capital of the Cook Islands, but the study made no mention of trachoma [79]. Another survey that focussed on eye health was carried out in 1980 [80]. Two of the 986 adults surveyed had superior limbic pannus. The study concluded trachoma was not a major cause of blindness, although the investigators did not directly check the conjunctiva for follicles or scars.

There was no mention of trachoma found during a 2002 assessment of ophthalmic records from a single hospital in the Cook Islands, although the authors do note the large amount of missing data due to poor record keeping [81].

Hawaii.

A 1956 study investigated the causes of blindness in Hawaii. Trachoma was not a cause of blindness in any of the 1677 people formally registered as blind [82].

Niue.

Around 47% of the population on Niue were examined for trachoma in 1945 [37]. 574/1867 were reported to be affected by trachoma but the age, gender and clinical disease profile of these individuals was not provided. Disease was reported as unevenly spatially distributed.

Samoa.

The earliest report found during the literature search was a 1914 investigation into epidemic eye disease in Samoa [83]. Leber and Prowazek noted that trachoma was present in Samoa alongside other eye diseases. [8385].

A small survey in 1945 found 135/245 of people had trachoma, although the criteria for participation, the clinical grade, the gender and age of those affected was not described [37]. A 1958 study examining over 700 adult ophthalmic outpatients and inpatients found 15 to have active trachoma and 24 to have visible trichiasis. Trachoma was deemed to be responsible for 10/136 cases of blindness [86]. In 1982, a survey of 510 patients found no cases of active trachoma but 19 patients with cicatricial entropions of the upper lids due to trachoma. A number of these patients had significant corneal scars and entropion surgery was performed [87]. Samples from Samoans of undefined age but with active trachoma were used in a thorough evaluation of laboratory methods for identifying ocular Ct infection. Of 20 specimens, 16 (80%) were seroreactive by microimmunefluorescence testing, but Ct could not be cultured in McCoy cells from any of these participants. Of those who were seropositive, 11 reacted strongly to serovar A antigens [60].

No record of trachoma was identified during a 2002 screening of 380 adult ophthalmic patient records from a single hospital in Samoa. Cataracts and refractive errors were cited as the major causes of visual impairment and blindness [45]. The most recent study focusing on eye health in Samoa was a review of clinical records from charitable outreach clinics between 2011–2013; no cases of trachoma were documented [33].

Tokelau.

In 1963, a general eye health survey was conducted throughout Tokelau. 98% of 1862 inhabitants were surveyed, and only one had follicles and pannus. 14 people had signs of severe or scarred trachoma, although these were suspected to be immigrant cases from Samoa [88].

Tonga.

A 1991 survey of binocular blindness in people living in randomly selected villages in Tonga concluded that three out of 4056 participants aged >20 years were blind in both eyes as a result of trachoma [89], although no further information was given on the method for evaluation and management of the cases that were found. No cases of trachoma were identified during two studies of patient records, one from a single clinic in Tonga (2002) [45] and the other from charitable outreach services (between 2011–2013) [33].

Discussion

A key question this study set out to address was what, if any, further mapping is needed to complete the baseline map of trachoma in the Pacific region. We found there to be only seven studies suitable for providing trachoma prevalence estimates. This highlights the paucity of data available to policy makers as they decide how best to manage trachoma in the Pacific region. This review has demonstrated the value of standardised data collection when making comparisons between surveys. Therefore, in those countries where further maping is required, we feel that mapping should adhere to standardised trachoma mapping strategies (TRA/PBPS). In addition, given the findings from the Solomon Islands, infection testing should become routine for trachoma mapping in the Pacific, and should also have a role in trachoma mapping elsewhere in the world. TRA-type targeted studies are not suitable for serological assessment given the small sample size and non-population-based sampling method, but NAAT testing for ocular Ct infection could be useful to determine the association between inflammation and infection. For PBPS-type district-level surveys, serological testing alongside NAATs has been a powerful tool in the mapping undertaken so far and should be incorporated as standard into future mapping efforts in the Pacific.

Solomon Islands, Kiribati and Vanuatu have the clearest picture of trachoma endemicity following recent, nationwide baseline mapping. In Kiribati, trachoma is clearly a public health problem, and further mapping can be postponed until SAFE interventions have had a chance to impact on trachoma prevalence. In the Solomon Islands and Vanuatu, the apparent paucity of TT and ocular Ct infection requires further investigation, particularly of the potential that TF has a causative origin that does not include bacterial infections. The data from recent studies of aetiology justifies a different approach to that utilised in Kiribati and other sub-Saharan African countries with similar TF prevalence. This could include cessation of MDA after a single round in districts with a TF prevalence of >10% in those aged 1–9 years. However, given the predictions of rapid population growth and potential for overcrowding in urban areas of Solomon Islands and Vanuatu [90], the F and E components of the SAFE strategy could still be justified alongside stringent surveillance to ensure the rate of ocular Ct transmission does not increase with the increase in population density.

The epidemiology of trachoma in PNG is similar to that of its Melanesian neighbours in the districts mapped so far, suggesting that it too may not require repeated rounds of MDA to reduce prevalence of Ct infection. The outcome of ongoing research activities in PNG, Solomon Islands and Vanuatu will be useful to guide mapping and treatment requirements. Review of ophthalmic records or deployment of the TRA protocol may be warranted in areas where trachoma has historically been described as more severe, such as East New Britain and West Sepik, to determine whether that remains the case. Infection testing should be incorporated to ensure the data is comparable to other areas in the Pacific. In Fiji, there is a need to further investigate the discrepancy between the two recent pre-MDA surveys in the Western Division; the outcome of those surveys and the other work in Melanesia will inform the subsequent intervention strategy. Where futher mapping is conducted, inclusion of infection testing (either through NAATs at the individual level or serology at the population level) could serve to further identify areas for targeted control. There is evidence of TF in Nauru, so population-based mapping is justified, again serological monitoring and infection testing may be useful here.

In Samoa, cases of active and scarring trachoma seem to have been identified in previous surveys, but no recent systematic data have been published. No eye-health data were identified in Tuvalu and very little from Tonga. These three independent Pacific Island states may face similar socioeconomic challenges to the independent Melanesian countries in terms of infrastructure and access to healthcare in rural areas, and may therefore be at risk of trachoma endemicity. As such, we believe use of the TRA protocol combined with NAAT infection testing is warranted unless the respective governing bodies of these countries have national disease surveillance data suggesting otherwise.

With the exception of American Samoa, where historic reports indicate trachoma has been a public health problem, no historical data were available from the majority of territories with economic links to developed nations included in this review (New Caledonia, Guam, Northern Mariana Islands, Pitcairn Islands, Wallis and Futuna and French Polynesia). The relationship between these states and developed nations mean that residents can move freely between them, and they enjoy greater economic stability, infrastructure and access to higher standards of healthcare. We therefore do not expect many risk factors for trachoma to be prevalent. Similarly, those in free association with New Zealand (Tokelau, Niue and Cook Islands) or the United States (Palau, Marshall Islands and Federated States of Micronesia) are also less likely to experience risk factors for trachoma. A handful of cases have been described in historic surveys of the causes of blindness; these are a tiny proportion of the whole and are poorly characterised, so we cannot be certain they meet definitions of trachoma by contemporary standards. If trachoma has been detected or is detected in the future during ongoing routine and targeted surveillance by respective governmental health services, a TRA could be a useful tool to assess whether more detailed mapping is required in these populations.

The second objective of this review was to identify whether any evidence could be found that may describe the temporal patterns of trachoma in this region over the past century. While good contemporary data on trachoma from recent population-based surveys is available, such robust evidence was almost absent amongst historical reports, with four key exceptions. The Pacific-wide mapping by Mann in the 1940s and 1950s [37], Ward’s surveys of Fiji [54], Dethlefs’ various surveys of trachoma in PNG [34] and Ostler’s and Thygeson’s surveys in American Samoa [78] stood out for their systematic nature and large scale. However these studies shared critical limitations as they did not differentiate between the various clinical signs of trachoma that were observed, nor were the participant selection procedures suitably random to allow extrapolation of prevalence estimates to areas outside of the specific islands and villages studied.

One key conclusion from the aggregated data is that ophthalmologists have consistently identified cases of the late stages of trachoma throughout the region between 1914 and 2018, but none have considered it to be worthy of special mention in general eye-health reports, nor have there been calls for or implementation of major strategies for clinical management of TT. Where it has been available by clinical outreach or in the routine clinical setting, uptake of TT surgery has been consistently low throughout the Pacific. Interestingly, the discrepancy observed between TF and TT in contemporary data has been alluded to a number of times in surveys in PNG [34]. From the contemporary mapping data available, countries with a predominantly Melanesian population seem to have low TT prevalence may be an artefact of the intensive mapping in these countries compared to elsewhere in the Pacific. However, that this has coincided with a low Ct prevalence may be an artefact of their being the most accurately mapped, or may lead some to propose that there are protective cultural or genetic factors related to Melanesian heritage. While such correlations can lead to over-interpretation, research into this phenomenon is ongoing.

There are limitations to this study. Firstly, the search method used did not include systematic assessment of grey literature databases nor request unpublished information from local stakeholders (for example, Ministries of Health and non-governmental organisations working in the region). If these search tools had been utilised, it is possible there would have been more studies to include in the review including information indicating data from countries that have been classed as non-endemic by the WHO. However, we wanted to ensure our findings were based on public information sources that could be independently verified. Secondly, although most of the articles retrieved by the literature search were accessible there were two conference abstracts that could not be accessed. Finally, some of the primary studies described in Mann’s book “Culture, Race, Climate and eye disease” were not accessible, so secondary data presented by Mann has been presented here.

This review has highlighted the heterogeneous pattern of trachoma throughout the Pacific. By summarising various studies and survey results into a single document, we hope to provide a resource for policymakers to identify key priority areas for mapping and further investigation in the peri-elimination period.

Supporting information

S1 Table. PRISMA checklist required by journal publication guidelines.

https://doi.org/10.1371/journal.pone.0207393.s001

(DOC)

S2 Table. Quality control questions used in the evaluation of trachoma studies.

https://doi.org/10.1371/journal.pone.0207393.s002

(DOCX)

S3 Table. A summary of all the articles included in this review.

This table includes the quality control assessment used on the prevalence studies.

https://doi.org/10.1371/journal.pone.0207393.s003

(DOC)

Acknowledgments

We are grateful to Aya Yajima (Western Pacific Regional Office, World Health Organization) for reviewing and providing feedback on the penultimate manuscript draft. We would also like to thank Saalim Koomar, Maximillian Ellebrecht and Aya Yajima for their support in translating articles in French, German and Japanese for this review.

References

  1. 1. Taylor HR. Trachoma: a blinding scourge from the Bronze Age to the twenty-first century. 1st ed. East Melbourne: Centre for Eye Research, Australia; 2008.
  2. 2. World Health Organization. Planning for the global elimination of trachoma (GET) Report of a WHO Consultation. World Health Organisation. 1996; 1–27. Available: http://apps.who.int/iris/bitstream/10665/66169/1/WHO_PBL_97.60.pdf?ua=1
  3. 3. World Health Assembly. WHA 51.11 Global elimination of blinding trachoma. 1998; 1–2. Available: http://www.who.int/neglected_diseases/mediacentre/WHA_51.11_Eng.pdf?ua=1
  4. 4. Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, Foster A. Trachoma control A guide for programme managers. World Health Organisation. 2006;
  5. 5. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65: 477–83. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2491032&tool=pmcentrez&rendertype=abstract pmid:3500800
  6. 6. World Health Organisation. WHO Report of the 2nd Global Scientific Meeting on Trachoma. 2003;44: 447–678.
  7. 7. Global Trachoma Atlas | Global Atlas of Trachoma [Internet]. [cited 23 Apr 2018]. Available: http://www.trachomaatlas.org/global-trachoma-atlas
  8. 8. Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK, et al. The genetic structure of Pacific Islanders. PLoS Genet. 2008;4: 0173–0190. pmid:18208337
  9. 9. Keeffe J, Taylor HR, Fotis K, Pesudovs K, Flaxman SR, Jonas JB, et al. Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010. Br J Ophthalmol. 2014;98: 586–591. pmid:24407561
  10. 10. International Agency for the Prevention of Blindness. Trachoma Mapping in the Pacific: Fiji, Solomon Islands and Kiribati. Melbourne, Australia; 2013.
  11. 11. Taleo F, Macleod CK, Marks M, Sokana O, Last AR, Willis R, et al. Integrated mapping of yaws and trachoma in the five northern-most provinces Vanuatu. PLoS Negl Trop Dis. United States; 2017;11: e0005267. pmid:28118354
  12. 12. Sokana O, Macleod C, Jack K, Butcher R, Marks M, Willis R, et al. Mapping Trachoma in the Solomon Islands: Results of Three Baseline Population-Based Prevalence Surveys Conducted with the Global Trachoma Mapping Project. Ophthalmic Epidemiol. England; 2016;23: 15–21. pmid:27937043
  13. 13. Macleod CK, Butcher R, Mudaliar U, Natutusau K, Pavluck AL, Willis R, et al. Low Prevalence of Ocular Chlamydia trachomatis Infection and Active Trachoma in the Western Division of Fiji. PLoS Negl Trop Dis. 2016;10. pmid:27404379
  14. 14. Butcher RMR, Sokana O, Jack K, Macleod CK, Marks ME, Kalae E, et al. Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naive Trachoma-Endemic Region of the Solomon Islands. PLoS Negl Trop Dis. United States; 2016;10: e0005051. pmid:27695076
  15. 15. Kama M, Cama A, Rawalai K, Koroivueta J. Active Ocular Trachoma In Fiji- A Population Based Prevalence Survey. Fiji J Public Heal. 2013;2: 11–17.
  16. 16. Ko R, Macleod C, Pahau D, Sokana O, Keys D, Burnett A, et al. Population-Based Trachoma Mapping in Six Evaluation Units of Papua New Guinea. Ophthalmic Epidemiol. 2016;23: 22–31. pmid:27893297
  17. 17. WPRO. Expert Consultation on Elimination of Trachoma in the Pacific. In: WPRO [Internet]. WHO Western Pacific Region; 2018 [cited 19 Jul 2018]. Available: http://www.wpro.who.int/mvp/meetings/ec_trachoma_2018/en/
  18. 18. Secretariat of the Pacific Community | Our Members [Internet]. [cited 23 Apr 2018]. Available: http://www.spc.int/our-members/
  19. 19. The World Factbook—Central Intelligence Agency [Internet]. [cited 23 Apr 2018]. Available: https://www.cia.gov/library/publications/the-world-factbook/geos/aq.html
  20. 20. World Health Organisation. Trachoma Status of Elimination [Internet]. [cited 23 Apr 2018]. Available: http://apps.who.int/neglected_diseases/ntddata/trachoma/trachoma.html
  21. 21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6: e1000097. pmid:19621072
  22. 22. Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Heal Policy Manag. 2014;3: 123–128. pmid:25197676
  23. 23. QGIS Development Team. QGIS Geographic Information System [Internet]. 2018. Available: http://qgis.osgeo.org
  24. 24. Kline K, Mccarthy JS, Pearson M, Loukas A, Hotez PJ. Neglected tropical diseases of Oceania: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. United States; 2013;7: e1755. pmid:23383349
  25. 25. Keeffe JE, Konyama K, Taylor HR. Vision impairment in the Pacific region. Br J Ophthalmol. 2002;86: 605–610. pmid:12034678
  26. 26. Polack S, Brooker S, Kuper H, Mariotti S, Mabey D, Foster A. Mapping the global distribution of trachoma. Bull World Health Organ. Switzerland; 2005;83: 913–919. pmid:16462983
  27. 27. Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya’ale D, Négrel A-D, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11: 67–115. pmid:15255026
  28. 28. Brethes B, Laille M. [Chlamydia trachomatis infections in New Caledonia. Study of 1,023 patients over a 12-month period]. Bull Soc Pathol Exot Filiales. France; 1987;80: 187–195. pmid:3608005
  29. 29. Schubert HCP. Trachoma and Other Eye Diseases in Western New Guinea. Assen, Netherlands: Van Gorcum; 1964.
  30. 30. Parsons GA. Ophthalmic practice in Papua New Guinea. P N G Med J. Papua New Guinea; 1975;18: 79–82.
  31. 31. Parsons GA, Adams J. Blindness in Papua New Guinea. P N G Med J. Papua New Guinea; 1987;30: 207–211. pmid:3478924
  32. 32. Parsons GA. A decade of opthalmic statistics in Papua New Guinea. P N G Med J. 1991;34: 255–261. pmid:1799087
  33. 33. Lees J, McCool J, Woodward A. Eye health outreach services in the Pacific Islands region: an updated profile. N Z Med J. 2015;128: 25–33.
  34. 34. Dethlefs R. The trachoma status and blindness rates of selected areas of Papua New Guinea in 1979–80. Aust J Ophthalmol. 1982;10: 13–18. pmid:7103858
  35. 35. Garap JN, Sheeladevi S, Shamanna BR, Nirmalan PK, Brian G, Williams C. Blindness and vision impairment in the elderly of Papua New Guinea. Clin Experiment Ophthalmol. 2006;34: 335–341. pmid:16764653
  36. 36. Lee L, D’Esposito F, Garap J, Wabulembo G, Koim SP, Keys D, et al. Rapid assessment of avoidable blindness in Papua New Guinea: a nationwide survey. Br J Ophthalmol. 2018; bjophthalmol-2018–311802. pmid:29793925
  37. 37. Mann I. Some Islands. Climate, race, culture and eye disease. 1st ed. Springfield, IL, USA: Charles C Thomas; 1966.
  38. 38. Mann I. Probable origins of trachoma in Australasia. Bull World Health Organ. 1957;16: 1165–1187. pmid:13479769
  39. 39. Mann I. Correlation of race and way of life in Australia and the territory of Papua and New Guinea with incidence and severity of clinical trachoma. Am J Ophthalmol. 1967;63: 1302–1309.
  40. 40. Mann I. Researches into the Regional Distribution of Eye Disease. Am J Ophthalmol. 1959;47: 134–144. pmid:13649852
  41. 41. MacCallan AF. The Epidemiology of Trachoma. Br J Ophthalmol. 1931;15: 369–411. pmid:18168968
  42. 42. Parsons GA. An occular survey of community school children in Madang Province. P N G Med J. 1982;25: 151–154. pmid:6984262
  43. 43. Heath M, Honeyman-Heath B. Trachoma and other disease in a New Guinea village. Am J Ophthalmol. 1973;75: 121–129. pmid:4684254
  44. 44. Andrist S, Yolton RL. Visual characteristics of natives in Fiji, South Pacific. J Am Optom Assoc. 1986;57.
  45. 45. Ramke J, Brian G, du Toit R. Eye disease and care at hospital clinics in Cook Islands, Fiji, Samoa and Tonga. Clin Experiment Ophthalmol. 2007;35: 627–634. pmid:17894682
  46. 46. Ramke J, Brian G, Maher L, Qalo Qoqonokana M, Szetu J. Prevalence and causes of blindness and low vision among adults in Fiji. Clin Experiment Ophthalmol. 2012;40: 490–6. pmid:22171580
  47. 47. Cama AT, Sikivou BT, Keeffe JE. Childhood visual impairment in Fiji. Arch Ophthalmol. 2010;128: 608–612. pmid:20457983
  48. 48. Stuppel R. Trachoma in Fiji- an Original Investigation. Biritsh J Opthalmology. 1933;17: 88–98.
  49. 49. MacCallan AF. Trachoma in the British Colonial Empire- Its Relation to Blindness; The Existing Means of Relief; Means of Prophylaxis. Biritsh J Opthalmology. 1934;18: 625–645.
  50. 50. Trachoma Bodian M. (A possible Carrier State). Arch Ophthalmol (Chicago, Ill 1960). 1947;38: 450–460.
  51. 51. Hope-Robertson WJ, Talbot LS. Investigation of Epidemic Eye Disease in fiji. N Z Med J. 1947;46: 122–129. pmid:20239278
  52. 52. Ching R. A New Trachoma Concept. AMA Arch Ophthalmol. 1954;51: 750–761. pmid:13157708
  53. 53. Swanston C. Trachoma in the Fiji Islands. Rev Int Trach. 1953;30: 374–394. pmid:13135064
  54. 54. Ward B. The prevalence of active trachoma in Fiji. Am J Ophthalmol. 1965;59: 458–63. pmid:14265582
  55. 55. Mathew AA, Keeffe JE, Le Mesurier RT, Taylor HR. Trachoma in the Pacific Islands: evidence from Trachoma Rapid Assessment. Br J Ophthalmol. 2009;93: 866–870. pmid:19174394
  56. 56. Macleod C, Yalen C, Butcher R, Mudaliar U, Natutusau K, Rainima-Qaniuci M, et al. Eyelash Epilation in the Absence of Trichiasis: Results of a Population-Based Prevalence Survey in the Western Division of Fiji. PLoS Negl Trop Dis. 2017;11: e0005277. pmid:28114364
  57. 57. Cocks N, Rainima-Qaniuci M, Yalen C, Macleod C, Nakolinivalu A, Migchelsen S, et al. Community seroprevalence survey for yaws and trachoma in the Western Division of Fiji. Trans R Soc Trop Med Hyg. 2016;110: 582–587. pmid:27852877
  58. 58. Verlee DL. An opthlamic survey in the Solomons Islands. Am J Ophthalmol. 1968;66: 304–319. pmid:5663368
  59. 59. Damon A. Human Ecology in the Solomon Islands: Biomedical Observations among Four Tribal Societies. Hum Ecol. 1974;2: 191–215.
  60. 60. Jones BR. Laboratory tests for chlamydial infection. Their role in epidemiological studies of trachoma and its control. Br J Ophthalmol. 1974;58: 438–454. pmid:4606714
  61. 61. Pikacha N. Trachoma in the Solomon Islands: Evidence from the trachoma rapid assesments. Clin Exp Ophthalmol. 2012;40: 63–118.
  62. 62. Mathew A. Trachoma in the Pacific Islands (Doctoral Thesis) [Internet]. University of Melbourne. 2014. Available: http://hdl.handle.net/11343/36557%5Cn/bitstream/handle/11343/36557/273807_Anu Mathew MD Thesis FINAL[1].pdf?sequence=1
  63. 63. Butcher R. Using alternate indicators to define need for public health intervention for trachoma: Evidence from the Pacific Islands (Doctoral Thesis). London School of Hygiene and Tropical Medicine. 2017.
  64. 64. Dawson CR, Jones BR, Sohrab Darougar. Blinding and non blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bull World Health Organ. 1975;52: 279–282. pmid:1084798
  65. 65. Dawson CR, Jones BR, Tarizzo ML, World Health Organization. Guide to trachoma control in programmes for the prevention of blindness. Geneva, Switzerland: World Health Organization; 1981.
  66. 66. Butcher R, Sokana O, Jack K, Sui L, Martin DL, Burton MJ, et al. Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis. Wellcome Open Res. 2018;3. pmid:29588922
  67. 67. Butcher R, Sokana O, Jack K, Kalae E, Sui L, Russell C, et al. Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associtate with Individual Non-Chlamydial Pathogens of the eye. Front Med. 2018;4. pmid:29410954
  68. 68. Vasileva H, Butcher R, Pickering H, Sokana O, Jack K, Solomon AW, et al. Conjunctival transcriptome profiling of Solomon Islanders with active trachoma in the absence of Chlamydia trachomatis infection. Parasites and Vectors. 2018;11: 1–8.
  69. 69. Newland HS, Harris MF, Walland M, McKnight D, Galbraith JE, Iwasaki W, et al. Epidemiology of blindness and visual impairment in Vanuatu. Bull World Health Organ. 1992;70: 369–372. pmid:1638666
  70. 70. Williams C, Szetu JL, Ramke J, Palagyi A, du Toit R, Brian G. Evaluation of the first 5 years of a national eye health programme in Vanuatu. Clin Experiment Ophthalmol. 2008;36: 162–167. pmid:18352874
  71. 71. Wessels IF, Markoff DD, Miller G. Project Canvas-Back in the Marshall Islands. Ophthalmic Surg. 1989;20: 745–751. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2616118 pmid:2616118
  72. 72. Yamamoto N, Sugata Y, Murakami K, Yamamoto Y. Causes of blindness and the results of cataract surgical intervention in the Micronesian islands: a retrospective study. Int Ophthalmol. 2004;25: 155–161. pmid:15847314
  73. 73. Negrel AD, Thylefors B. Operational Applications of the Simplified Coding of Trachoma and its Complications. Rev Int Trach. 1992;69: 97–105.
  74. 74. Tekeraoi R, Cama A. The prevalence and causes of vision loss in urban areas of Kiribati. Clin Experiment Ophthalmol. 2014;42: 41–62. Available: http://www.flickr.com/photos/photo-dieter/3061241214/
  75. 75. Cromwell EA, Courtright P, King JD, Rotondo LA, Ngondi J, Emerson PM. The excess burden of trachomatous trichiasis in women: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. Royal Society of Tropical Medicine and Hygiene; 2009;103: 985–992. pmid:19362326
  76. 76. Cama A, Müller A, Taoaba R, Butcher RMR, Itibita I, Migchelsen SJ, et al. Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. PLoS Negl Trop Dis. 2017;11. pmid:28898240
  77. 77. Harbert M. Trachoma in American Samoa. Rev Int Trach. 1938;21: 406–412.
  78. 78. Ostler B, Thygeson P. Trachoma in American Samoa. Rev Int Trach. 1973;50: 7–29.
  79. 79. Faine S, Hercus CE. Infections in Rarotonga, Cook Islands. Trans R Soc Trop Med Hyg. 1951;1 graph: 27 ref. http://dx.doi.org/10.1016/S0035-9203(51)80005-1
  80. 80. Heriot WJ, Crock GW, Taylor R, Zimmet P. Ophthalmic findings among one thousand inhabitants of Rarotonga, Cook Islands. Aust J Ophthalmol. 1983;11: 81–94. pmid:6870693
  81. 81. Ramke J, Brian G, du Toit R. Eye disease and care at hospital clinics in Cook Islands, Fiji, Samoa and Tonga. Clin Exp Ophthalmol. 2007;35: 627–634. pmid:17894682
  82. 82. Pinkerton F J. Blindness in Hawaii: A Report on All Registered Blind to December 31, 1955. Hawaii Med J. 1956;16.
  83. 83. Leber A, Prowazek S. Epitheliosis desquamativa der Sudsee. Graefe’s Arch Clin Exp Ophthalmol. 1914;87.
  84. 84. Kluxen G, Bernsmeier H. [Endemic eye diseases in Samoa, 1910–1913]. Klin Monbl Augenheilkd. 1979;175: 841–845. pmid:552013
  85. 85. Kluxen G, Bernsmeier H. Endemic ocular infections of the South Seas in the German Colonial. P N G Med J. 1980;23: 197–199. pmid:7008429
  86. 86. Elliot R. Opthalmic Disease in Western Samoa. Trans Ophthalmol Soc N Z. 1960;12: 87–97. pmid:13726453
  87. 87. Egbert PR. Ophthalmic disease in Western Samoa. Aust N Z J Ophthalmol. 1986;14: 167–170. pmid:3801207
  88. 88. Elliot R. An Opthalmic Survey of the Tokelau Islands. Trans Ophthalmol Soc N Z. 1965;17: 25–35. pmid:5217226
  89. 89. Newland HS, Woodward AJ, Taumoepeau LA, Karunaratne NS, Duguid IG. Epidemiology of blindness and visual impairment in the kingdom of Tonga. Br J Ophthalmol. 1994;78: 344–348. pmid:8025066
  90. 90. Firth S. Instability in the Pacific Islands: A status report [Internet]. Lowy Institute. 2018. Available: https://www.lowyinstitute.org/sites/default/files/documents/Firth_Instability in the Pacific Islands_A status report_WEB.pdf